Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including melanoma, lung cancer, head and neck cancer, bladder cancer, cervical cancer, liver cancer, stomach cancer, breast cancer, lymphoma, and to treat patients with any type of solid tumor that is microsatellite instability–high or mismatch repair–deficient.
Persistent infections from pathogens are a major cause of cancer incidence worldwide. An analysis from 2012 indicates that more than 15 percent of new cancer cases were attributed to carcinogenic infection, and the top...
Cancer immunotherapy research has exploded in recent years. This treatment utilizes a patient’s own immune system to recognize and attack cancer cells. While many successful immunotherapeutic regimens have relied on checkpoint inhibition, other immunotherapeutic approaches, such as adoptive cellular therapies (ACT), the use of bispecific antibodies, and targeting components of the tumor microenvironment, are showing promise in a variety of cancer types.
A pair of studies presented at the AACR Annual Meeting 2019 demonstrated encouraging clinical outcomes with two different chimeric antigen receptor (CAR) T-cell therapies for patients with advanced solid tumors.
Recent advances in cancer research has led to enormous progress against many cancer types. From 1991 to 2015, we witnessed a 26 percent reduction in the U.S. cancer death rate, representing over 2 million...
The AACR Annual Meeting 2019 features the theme “Integrative Cancer Science • Global Impact • Individualized Patient Care.” That theme provided the structure for Monday’s plenary session, when cancer researchers representing three continents, four cancer types,...
Cancer prevention refers to measures that people can take to reduce their risk of developing cancer. These measures can include lifestyle changes, like eliminating tobacco use, maintaining a healthy weight, staying active, and limiting...
The spectacular sight of the AACR Annual Meeting 2019 Opening Ceremony, held Sunday, March 31, at the Georgia World Congress Center in Atlanta was immediately followed by a splendid opening plenary session, titled “Achieving...
Non-Hispanic black men in the United States are much more likely to develop prostate cancer and to die from the disease than their non-Hispanic white counterparts. Many factors contribute to this striking disparity, including...
Colorectal cancer is the second leading cause of cancer death in the United States. More than 50,000 people are estimated to have died from colorectal cancer in the United States last year, according to...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More